EUVIMEDEUVIMED entdecken
Vergleichsstudie

Post‐authorization safety study to assess the risk of diabetic ketoacidosis among type 2 diabetes mellitus patients treated with ertugliflozin compared to patients treated with other antihyperglycaemic agents in a Medicare and Medicaid population

Ashish Rai iD, James Marshall, Sampada Nandyala, Meg Her, Anna A Agan, Ting-Ying Huang iD, Carla Rodriguez-Watson, Alecia Clary, Brandon Diessner iD, Margaret B Nolan, Djeneba Audrey Djibo iD, Andrea DeVries und 10 weitere

Diabetic Medicine · 2026

DOI: 10.1111/dme.70208 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Diabetic Medicine, 2026. Verfasst von Ashish Rai und 21 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Diabetic Ketoacidosis, Bridged Bicyclo Compounds, Heterocyclic. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Pfizer Inc US, Merck Sharp & Dohme LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To evaluate diabetic ketoacidosis (DKA) risk among new users of ertugliflozin versus sulfonylureas (SU) or thiazolidinediones (TZD) and incretin‐based drugs in patients with type 2 diabetes.

Methods

We used Medicare and Medicaid fee‐for‐service adjudicated claims within the Innovation in Medical Evidence and Development Surveillance network to identify three new‐user cohorts: (1) ertugliflozin; (2) SU/TZD; and (3) incretin‐based drugs. The outcome was a principal hospital discharge diagnosis for DKA. Adjusted hazard ratios (HRs) were estimated after 1:1 propensity score (PS) matching, separately for ertugliflozin vs. SU/TZD and vs. incretin‐based drugs. Subgroup analyses were performed based on baseline insulin use.

Results

After PS matching, baseline characteristics were similarly distributed in each cohort. For ertugliflozin ( n = 42,907) vs. SU/TZD ( n = 42,907), the incidence rates of DKA per 1000 person‐years (PY) were 2.95 and 1.49, respectively. For ertugliflozin ( n = 42,247) vs. incretin‐based drugs ( n = 42,247), the incidence rates of DKA per 1000 PY were 2.76 and 1.06, respectively. For ertugliflozin vs. SU/TZD, the HR [95% confidence interval (CI)] was 1.88 [1.17–3.02]; in non‐insulin users, 2.34 [1.27–4.31]; and in insulin users, 1.17 [0.54–2.52]. For ertugliflozin vs. incretin‐based drugs, the HR [95% CI] was 2.40 [1.40–4.11]; in non‐insulin users, 2.84 [1.42–5.66]; and in insulin users, 1.87 [0.79–4.46].

Conclusions

Ertugliflozin was associated with a higher risk of DKA relative to comparators. HRs were higher among new users with no‐concomitant insulin use than those with concomitant insulin use. Results were consistent with prior SGLT2i data and highlighted the importance of caution by both patients and physicians.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsDiabetic KetoacidosisBridged Bicyclo Compounds, HeterocyclicSodium-Glucose Transporter 2 InhibitorsHumansUnited StatesFemaleMaleAgedMedicareMedicaidSulfonylurea CompoundsThiazolidinedionesMiddle AgedInsulin SecretagoguesIncretinsProduct Surveillance, Postmarketing

Stichwörter der Autor:innen

SGLT2 inhibitorantidiabetic drugcohort studydiabetic ketoacidosistype 2 diabetes

Substanzen

ertugliflozinHypoglycemic AgentsBridged Bicyclo Compounds, HeterocyclicSulfonylurea CompoundsThiazolidinedionesSodium-Glucose Transporter 2 InhibitorsInsulin SecretagoguesIncretins

Autor:innen und Institutionen

  • Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
  • Reagan-Udall Foundation for the FDA, Washington, DC, USA.
  • Evidence to Practice, Durham, North Carolina, USA.
  • Optum Life Sciences, Boston, Massachusetts, USA.
  • HealthPartners Institute, Bloomington, Minnesota, USA.

ORCID-Profile: Ashish Rai, Ting-Ying Huang, Brandon Diessner, Djeneba Audrey Djibo, Ravi Shankar, Precious Ejelonu, Robert Frederich, Urszula Masiukiewicz, Sengwee Toh

Förderung

  • Pfizer Inc US
  • Merck Sharp & Dohme LLC

Zitieren

APA

Rai, A., Marshall, J., Nandyala, S., Her, M., Agan, A. A., Huang, T. Y., Rodriguez-Watson, C., Clary, A., Diessner, B., Nolan, M. B., Djibo, D. A., DeVries, A., Daniels, K., Zhang, X., Wang, T., Gantz, I., Shankar, R., Zale, M. M., Ejelonu, P., …, & Toh, S. (2026). Post‐authorization safety study to assess the risk of diabetic ketoacidosis among type 2 diabetes mellitus patients treated with ertugliflozin compared to patients treated with other antihyperglycaemic agents in a Medicare and Medicaid population. Diabetic Medicine. https://doi.org/10.1111/dme.70208

Vancouver

Rai A, Marshall J, Nandyala S, Her M, Agan AA, Huang TY, et al. Post‐authorization safety study to assess the risk of diabetic ketoacidosis among type 2 diabetes mellitus patients treated with ertugliflozin compared to patients treated with other antihyperglycaemic agents in a Medicare and Medicaid population. Diabetic Medicine. 2026. doi:10.1111/dme.70208

BibTeX
@article{Rai2026,
  author = {Rai, Ashish and Marshall, James and Nandyala, Sampada and Her, Meg and Agan, Anna A and Huang, Ting-Ying and Rodriguez-Watson, Carla and Clary, Alecia and Diessner, Brandon and Nolan, Margaret B and Djibo, Djeneba Audrey and DeVries, Andrea and Daniels, Kimberly and Zhang, Xiao and Wang, Tongtong and Gantz, Ira and Shankar, Ravi and Zale, Melissa MacCoy and Ejelonu, Precious and Frederich, Robert and Masiukiewicz, Urszula and Toh, Sengwee},
  title = {Post‐authorization safety study to assess the risk of diabetic ketoacidosis among type 2 diabetes mellitus patients treated with ertugliflozin compared to patients treated with other antihyperglycaemic agents in a Medicare and Medicaid population},
  journal = {Diabetic Medicine},
  year = {2026},
  doi = {10.1111/dme.70208}
}
Kostenlos starten →